Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Rising Today

By Keith Speights - Jun 25, 2021 at 11:28AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its momentum from good news earlier this week is continuing.

What happened

Shares of Moderna (MRNA -5.06%) were rising 2% as of 11:04 a.m. EDT on Friday. The company didn't report any new developments. Instead, the stock appears to still be benefiting from good news earlier this week as well as strength in the overall stock market.

So what

There were two positive developments for Moderna this week. The company won a deal with the European Commission to supply another 150 million doses of its COVID-19 vaccine in 2022. And investors were relieved that the only action taken in response to a potential link between messenger RNA COVID vaccines and rare heart inflammation issues was that the Food and Drug Administration is adding a warning to the vaccines' labels.

Healthcare professional holding a syringe with needled and a vaccine vial.

Image source: Getty Images.

These two stories are both good signs that Moderna remains one of the juggernauts in the global COVID vaccine market (along with Pfizer and its partner BioNTech). Even without the two developments, though, it's possible that the biotech stock would have risen today thanks to the solid overall stock market gains. A rising tide really does usually lift all boats.

Now what

Moderna should report increasing revenue and profits in its upcoming quarterly updates thanks to the success of its COVID vaccine. A key wild card for the company is whether or not booster doses will be needed, and if so, how frequently they'll be required. 

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$150.00 (-5.06%) $-8.00
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$48.58 (-1.40%) $0.69
BioNTech SE Stock Quote
BioNTech SE
BNTX
$147.61 (-2.91%) $-4.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.